Owlstone Medical is developing a breathalyzer for disease. Our mission is to save 100,000 lives and $1.5B in healthcare costs by advancing early detection and precision medicine.
Non-invasive breath biomarkers for early detection and precision medicine
Owlstone Medical is developing a breathalyzer for disease. With a goal to find ways to improve non-invasive diagnostics for respiratory diseases, liver diseases, cancer, digestive health and other conditions. Our mission is to save 100,000 lives and $1.5B in healthcare costs by advancing early detection and precision medicine.
Breath Biopsy® aims to develop a new diagnostic modality making it possible to discover novel non-invasive biomarkers in breath using a platform with the potential to transition to point-of-care. The award-winning ReCIVA® Breath Sampler ensures reliable collection of breath samples. The volatile organic compounds (VOCs) present in breath are analyzed using state of the art chemical analysis technologies. Our aim is to develop tools, potentially based on our proven microchip chemical sensor technology (FAIMS), to detect validated biomarkers of disease.
The Breath Biopsy platform provides biomarker discovery and validation capabilities to support development of applications in precision medicine for a wide range of other medical conditions. Highly sensitive and selective, our platform allows for early diagnosis when treatments are more effective and more lives can be saved.
Owlstone Medical is involved in studies related to major and rapidly growing health concerns including lung cancer, asthma and liver disease. We are also participants in extensive partnerships focusing on multiple cancer types, pulmonary hypertension, mesothelioma, workplace exposures and much more.
Our Breath Biopsy Products and Services are available to academic, clinical and pharma research partners who want to develop breath based diagnostics for their own applications.
At Owlstone Medical, everyone makes a difference
We are on a mission to save 100k lives and $1.5Bn healthcare costs. We can only do this if we have the very best scientists and engineers. If that is you, we would love to hear from you....
Take control of your gut health with OMED Health
It has been estimated that 12% of the UK population suffers from IBS, a condition characterized by persistent digestive problems, and it may be the case that a large proportion of IBS may be actually due to conditions such as SIBO, or food intolerances.
We are excited to announce OMED Health. We aim to pinpoint your digestive health problems with at-home breath testing and professional analysis of the gases in exhaled breath.
As respected world leaders in breath analysis we offer simple, reliable breath tests and access to qualified experts. You’ll get advice you can trust and the guidance you need to take control of your gut health symptoms, to move forward with improved comfort and confidence.
Our latest updates
Gut & Digestion
Pharmaforum Article: How breath analysis could help those living with gut health issues like IBS
Owlstone Medical Wins Contract from U.S. Department of Defense to Develop Handheld Breath Biopsy Device for Early Infectious Disease Detection
Gut & Digestion